Eisai sues FDA over shortened marketing period for 2 drugs

Eisai filed a lawsuit to force the FDA to extend the drugmaker's marketing exclusivity period on diet drug Belviq and epilepsy drug Fycompa after listing delays by the U.S. Drug Enforcement Agency delayed the drugs' launch, thus shortening the marketing exclusivity period.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC